Gain Therapeutics, Inc. (GANX) — 8-K Filings

8-K Filings (26)

• 8-K Filing — Mar 26, 2026
• Gain Therapeutics Files 8-K Report — Dec 18, 2025 Risk: low
  On December 18, 2025, Gain Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure, with no specific detai
• Gain Therapeutics Files 8-K — Nov 28, 2025 Risk: low
  Gain Therapeutics, Inc. filed an 8-K on November 28, 2025, reporting other events and financial statements. The filing does not contain specific details about t
• 8-K Filing — Nov 12, 2025
• Gain Therapeutics Files 8-K — Oct 14, 2025 Risk: low
  Gain Therapeutics, Inc. filed an 8-K on October 14, 2025, to report on Regulation FD disclosures and financial statements. The filing provides information on th
• Gain Therapeutics Announces Board and Compensation Changes — Oct 9, 2025 Risk: medium
  Gain Therapeutics, Inc. announced on October 6, 2025, a change in its board of directors and executive compensation arrangements. Specifically, the company repo
• Gain Therapeutics Files 8-K: Details Pending — Oct 6, 2025 Risk: medium
  Gain Therapeutics, Inc. filed an 8-K on October 6, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events
• Gain Therapeutics Files 8-K: Material Agreement & Equity Sales — Jul 17, 2025 Risk: medium
  Gain Therapeutics, Inc. announced on July 15, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equit
• Gain Therapeutics Files 8-K Report — Jun 30, 2025 Risk: medium
  On June 30, 2025, Gain Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure, with no specific details p
• Gain Therapeutics Files 8-K on Corporate Updates — Jun 24, 2025 Risk: low
  Gain Therapeutics, Inc. filed an 8-K on June 24, 2025, reporting on several key corporate events. These include amendments to its articles of incorporation or b
• Gain Therapeutics Files 8-K — Apr 10, 2025 Risk: low
  Gain Therapeutics, Inc. filed an 8-K on April 10, 2025, reporting on other events and financial statements. The filing does not contain specific details about n
• Gain Therapeutics Files 8-K — Feb 6, 2025 Risk: low
  Gain Therapeutics, Inc. filed an 8-K on February 6, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contai
• Gain Therapeutics Faces Delisting Concerns — Jan 15, 2025 Risk: high
  Gain Therapeutics, Inc. filed an 8-K on January 15, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a tran
• Gain Therapeutics Appoints New CMO, Director — Jan 7, 2025 Risk: low
  Gain Therapeutics, Inc. announced on January 6, 2025, the appointment of Dr. Marcella R. Ridgeway as Chief Medical Officer and the election of Ms. Jennifer L. J
• Gain Therapeutics Files 8-K — Dec 23, 2024 Risk: low
  Gain Therapeutics, Inc. filed an 8-K on December 23, 2024, reporting on events including Regulation FD disclosures, other events, and financial statements. The
• Gain Therapeutics Files 8-K — Oct 21, 2024 Risk: medium
  Gain Therapeutics, Inc. filed an 8-K on October 21, 2024, to report other events. The filing does not contain specific details about the nature of these events,
• Gain Therapeutics Files 8-K — Oct 8, 2024 Risk: low
  Gain Therapeutics, Inc. filed an 8-K on October 8, 2024, reporting on events that occurred on October 7, 2024. The filing includes information related to Regula
• Gain Therapeutics Files 8-K for Material Agreement — Sep 6, 2024 Risk: medium
  Gain Therapeutics, Inc. filed an 8-K on September 6, 2024, to report a material definitive agreement and financial statements. The filing does not disclose spec
• Gain Therapeutics to be Delisted from Nasdaq — Jul 12, 2024 Risk: high
  Gain Therapeutics, Inc. announced on July 11, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The com
• Gain Therapeutics Files 8-K — Jul 9, 2024 Risk: low
  Gain Therapeutics, Inc. filed an 8-K on July 9, 2024, reporting an event under Regulation FD Disclosure and Other Events. The filing includes financial statemen
• Gain Therapeutics Appoints New CMO, CSO, and Director — Jun 28, 2024 Risk: medium
  Gain Therapeutics, Inc. announced on June 25, 2024, the appointment of Dr. Marcella R. Ridgeway as Chief Medical Officer and Dr. David M. Recker as Chief Scient
• Gain Therapeutics Files 8-K on Shareholder Vote — Jun 25, 2024 Risk: low
  Gain Therapeutics, Inc. filed an 8-K on June 25, 2024, reporting on matters submitted to a vote of its security holders on June 24, 2024. The filing does not di
• Gain Therapeutics Enters Material Definitive Agreement — Jun 14, 2024 Risk: medium
  Gain Therapeutics, Inc. announced on June 13, 2024, that it entered into a material definitive agreement. The filing also includes financial statements and exhi
• Gain Therapeutics Appoints New CMO and CSO, O'Connell Departs — Apr 8, 2024 Risk: medium
  Gain Therapeutics, Inc. announced on April 5, 2024, the appointment of Dr. Marcella R. Ridgeway as Chief Medical Officer and Dr. Jonathan M. Roth as Chief Scien
• Gain Therapeutics Files 8-K on Officer/Director Changes — Feb 22, 2024 Risk: medium
  Gain Therapeutics, Inc. filed an 8-K on February 22, 2024, reporting an event that occurred on February 19, 2024. The filing pertains to Item 5.02, specifically
• Gain Therapeutics Files 8-K, Confirms Emerging Growth Status — Jan 31, 2024
  Gain Therapeutics, Inc. filed an 8-K on January 31, 2024, primarily to disclose information under Regulation FD and to include financial statements and exhibits

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX